# Teleflex Announces Third Quarter 2025 Earnings Conference Call Information and Vascular Intervention Investor Virtual Meeting Details
Canonical URL: https://biopharmsignal.com/news/TFX/teleflex-announces-third-quarter-2025-earnings-conference-call-information-and-v-910c02b8
Ticker: TFX
Company: Teleflex
Source: Teleflex
Published: 2025-10-16 20:30 EST
## Summary

Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its third quarter financial results...

## Article Body
Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its third quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, November 6, 2025.

To participate in the conference call, please utilize this link to pre-register and receive the dial-in information. The call can also be accessed through a live audio webcast on the company’s website, teleflex.com .

An audio replay of the call will be available beginning at 11:00 am Eastern Time on November 6, 2025, either on the Teleflex website or by telephone. The call can be accessed by dialing 1 800 770 2030 (U.S. and Canada) or 1 609 800 9909 (all other locations). The conference ID is 69028.

Vascular Intervention Virtual Meeting

On November 14, 2025, at 8:00 am Eastern Time, Teleflex will host a virtual meeting to review its recent Vascular Intervention business acquisition, with a focus on the strategic rationale and the comprehensive coronary and peripheral product portfolio.

To participate in the investor event, please utilize this link to pre-register and receive the dial-in information. The call can also be accessed through a live audio webcast on the company’s website, teleflex.com .

About Teleflex Incorporated

As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare.

Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™ Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose.

At Teleflex, we are empowering the future of healthcare. For more information, please visit teleflex.com .

Contacts: Teleflex Incorporated: Lawrence Keusch Vice President, Investor Relations and Strategy Development

investors.teleflex.com 610-948-2836
## Recent Company News
- 2026-01-08 11:30 EST — [Teleflex Announces Leadership Transition](https://biopharmsignal.com/news/TFX/teleflex-announces-leadership-transition-d572754c) — Source: Teleflex
- 2025-12-09 14:04 EST — [Teleflex Announces Sale of Acute Care, Interventional Urology, and OEM Businesses for $2.03 Billion](https://biopharmsignal.com/news/TFX/teleflex-announces-sale-of-acute-care-interventional-urology-and-oem-businesses--da92348c) — Source: Teleflex
- 2025-11-14 11:30 EST — [Teleflex to Present at the Jefferies Global Healthcare Conference in London](https://biopharmsignal.com/news/TFX/teleflex-to-present-at-the-jefferies-global-healthcare-conference-in-london-78b44fb9) — Source: Teleflex
- 2025-11-06 11:45 EST — [Teleflex Announces Quarterly Dividend](https://biopharmsignal.com/news/TFX/teleflex-announces-quarterly-dividend-b49b5009) — Source: Teleflex
- 2025-11-06 11:30 EST — [Teleflex Reports Third Quarter Financial Results and Full Year 2025 Outlook](https://biopharmsignal.com/news/TFX/teleflex-reports-third-quarter-financial-results-and-full-year-2025-outlook-7e2975be) — Source: Teleflex
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)